Development
Moderna, Inc.
MRNA
$25.35
-$1.77-6.53%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -156.37% | -129.46% | -91.41% | -67.32% | -31.47% |
| Total Depreciation and Amortization | 78.45% | 44.22% | 19.80% | 17.23% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 506.57% | 374.82% | -29.78% | -124.08% | -124.59% |
| Change in Net Operating Assets | 95.98% | 95.37% | 69.56% | -178.74% | -364.14% |
| Cash from Operations | -162.60% | -131.35% | -102.34% | -92.60% | -63.43% |
| Capital Expenditure | -76.75% | -35.28% | -20.55% | 0.00% | -40.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 204.65% | 190.12% | 149.07% | 110.28% | 42.03% |
| Cash from Investing | 181.26% | 170.19% | 140.39% | 106.16% | 39.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -46.74% | -23.95% | -21.29% | -5.33% | -31.43% |
| Issuance of Common Stock | -27.69% | -16.18% | -31.46% | -42.59% | -47.58% |
| Repurchase of Common Stock | 65.33% | 58.88% | 7.78% | -118.38% | -288.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 60.06% | 56.06% | 5.45% | -117.26% | -294.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.07% | 96.51% | 134.33% | -306.87% | -186.25% |